One of these reports , the joint analysis of North Central Cancer Treatment Group NCCTG N@ ( Combination Chemotherapy With or Without Trastuzumab in Treating Women With HER@-Overexpressing Breast Cancer ) and the National Surgical Adjuvant Breast and Bowel Project NSABP B-@ ( Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER@ ) , was updated in @ .